AtaiBeckley Inc. competitors & alternatives

Similar pharmaceuticals company

GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.

Similar pharmaceuticals company

Clearmind Medicine Inc. is a pre-clinical biopharmaceutical company dedicated to pioneering the development of novel psychedelic-based treatments. Their primary goal is to address a variety of mental health and addiction challenges that currently lack adequate solutions. The company's research targets conditions such as alcohol use disorder (including problematic binge drinking), various eating disorders (like binge eating), depression, and other compulsive or "binge" behaviors. Founded in 2017, the company initially operated under the name Cyntar Ventures Inc. before officially rebranding as Clearmind Medicine Inc. in March 2021. Its operations are headquartered in Vancouver, Canada.

Helus Pharma Inc.PharmaceuticalsUnited States

66% match

Similar pharmaceuticals company

Helus Pharma Inc. advances mental health treatments by developing novel, second-generation therapies, proprietary drug delivery systems, and patent-protected molecules. The company serves the healthcare and pharmaceutical sectors.

H LUNDBECK A/S H. LUNDBECK0ABR · PharmaceuticalsUnited Kingdom

64% matchPublic

Similar pharmaceuticals company

H. Lundbeck A/S is a global pharmaceutical company that specializes exclusively in the research, development, and commercialization of therapies for brain diseases. It provides treatments for various neurological and psychiatric conditions, such as migraine, Parkinson's disease, Alzheimer's disease, depression, and schizophrenia, serving patients worldwide.

Biotech

ATAI Life Sciences AG is a biopharmaceutical company headquartered in Munich, Germany, focused on acquiring and developing innovative treatments for mental health disorders.

Beckley PsytechBiotechUnited States

76% matchAI 17/100Green 4/100

Biotech

Beckley Psytech is a UK-based clinical-stage biotechnology company developing psychedelic medicines for psychiatric and neurological disorders. Its programs have included BPL-003, an intranasal formulation of 5-MeO-DMT, intended for conditions such as treatment-resistant depression and alcohol use disorder.

Biotechnology

COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.

Reunion Neuroscience Management, Inc.BiotechnologyUnited States

70% match

Biotechnology

Reunion Neuroscience is a clinical-stage biopharmaceutical company that develops innovative therapeutics for underserved mental health disorders. Its lead drug candidate, luvesilocin, is a proprietary 5-HT2A agonist designed to provide durable antidepressant effects for patients with mood and anxiety disorders.

Gilgamesh Pharma Inc.BiotechnologyUnited States

69% match

Biotechnology

Gilgamesh Pharma Inc. is a clinical-stage neuroscience company that develops novel chemical entities to treat psychiatric diseases, aiming to move beyond symptom management toward rapid-acting and durable therapies. The company utilizes an AI-powered discovery platform and medicinal chemistry to create precision therapies targeting conditions such as depression, anxiety, addiction, and schizophrenia.

Biotechnology

Lykos Therapeutics is a biotechnology company developing psychedelic-assisted therapies, particularly MDMA-assisted therapy for post-traumatic stress disorder (PTSD). It works with clinicians and researchers to advance regulated treatments for people with PTSD and related mental-health conditions.

Life Sciences (Therapeutics)

Eumentis Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California, dedicated to developing novel therapies for serious neuropsychiatric conditions.

Biotechnology

Intra-Cellular Therapies was a U.S. biopharmaceutical company focused on developing treatments for central nervous system disorders. Its principal product, CAPLYTA (lumateperone), is used to treat schizophrenia and depressive episodes associated with bipolar disorder in adults, serving patients and mental-healthcare providers.